Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer's disease

Christopher Carlson, Eric Siemers, Ann Hake, Michael Case, Roza Hayduk, Joyce Suhy, Joonmi Oh, Jerome Barakos

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Introduction: Solanezumab, a humanized monoclonal antibody that binds soluble amyloid beta peptide, is being developed for treatment of Alzheimer's disease (AD). Methods: Patients (n = 2042) with mild and moderate AD were randomized 1:1 to 400-mg solanezumab or placebo infusion every 4 weeks for 80 weeks and 1457 patients entered an open-label extension. Magnetic resonance imaging scans monitored for amyloid-related imaging abnormalities-edema/effusion (ARIA-E) and amyloid-related imaging abnormalities-hemorrhage/hemosiderin deposition. Results: Sixteen patients (solanezumab, n = 11; placebo, n = 5) developed ARIA-E during the double-blind phase, and 7 patients developed ARIA-E during the open-label extension as of July 31, 2014. Unique cases are discussed including solanezumab patients who were given solanezumab, while ARIA-E was present and a patient who developed ARIA-E during placebo treatment and again during solanezumab treatment. Discussion: Asymptomatic ARIA-E was detected in solanezumab-treated and placebo-treated AD patients. ARIA-E occurs infrequently during solanezumab and placebo treatments but may occur repeatedly in some patients.

Original languageEnglish (US)
Pages (from-to)75-85
Number of pages11
JournalAlzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
Volume2
DOIs
StatePublished - 2016

Fingerprint

solanezumab
Amyloid
Alzheimer Disease
Edema
Placebos
Hemosiderin
Antibodies, Monoclonal, Humanized
Amyloid beta-Peptides
Therapeutics

Keywords

  • Alzheimer's disease
  • Amyloid-related imaging abnormalities
  • Clinical trials

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Neurology

Cite this

Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer's disease. / Carlson, Christopher; Siemers, Eric; Hake, Ann; Case, Michael; Hayduk, Roza; Suhy, Joyce; Oh, Joonmi; Barakos, Jerome.

In: Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, Vol. 2, 2016, p. 75-85.

Research output: Contribution to journalArticle

Carlson, Christopher ; Siemers, Eric ; Hake, Ann ; Case, Michael ; Hayduk, Roza ; Suhy, Joyce ; Oh, Joonmi ; Barakos, Jerome. / Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer's disease. In: Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring. 2016 ; Vol. 2. pp. 75-85.
@article{aa7d60b332ce44eb96303baa7be8d5f4,
title = "Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer's disease",
abstract = "Introduction: Solanezumab, a humanized monoclonal antibody that binds soluble amyloid beta peptide, is being developed for treatment of Alzheimer's disease (AD). Methods: Patients (n = 2042) with mild and moderate AD were randomized 1:1 to 400-mg solanezumab or placebo infusion every 4 weeks for 80 weeks and 1457 patients entered an open-label extension. Magnetic resonance imaging scans monitored for amyloid-related imaging abnormalities-edema/effusion (ARIA-E) and amyloid-related imaging abnormalities-hemorrhage/hemosiderin deposition. Results: Sixteen patients (solanezumab, n = 11; placebo, n = 5) developed ARIA-E during the double-blind phase, and 7 patients developed ARIA-E during the open-label extension as of July 31, 2014. Unique cases are discussed including solanezumab patients who were given solanezumab, while ARIA-E was present and a patient who developed ARIA-E during placebo treatment and again during solanezumab treatment. Discussion: Asymptomatic ARIA-E was detected in solanezumab-treated and placebo-treated AD patients. ARIA-E occurs infrequently during solanezumab and placebo treatments but may occur repeatedly in some patients.",
keywords = "Alzheimer's disease, Amyloid-related imaging abnormalities, Clinical trials",
author = "Christopher Carlson and Eric Siemers and Ann Hake and Michael Case and Roza Hayduk and Joyce Suhy and Joonmi Oh and Jerome Barakos",
year = "2016",
doi = "10.1016/j.dadm.2016.02.004",
language = "English (US)",
volume = "2",
pages = "75--85",
journal = "Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring",
issn = "2352-8729",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer's disease

AU - Carlson, Christopher

AU - Siemers, Eric

AU - Hake, Ann

AU - Case, Michael

AU - Hayduk, Roza

AU - Suhy, Joyce

AU - Oh, Joonmi

AU - Barakos, Jerome

PY - 2016

Y1 - 2016

N2 - Introduction: Solanezumab, a humanized monoclonal antibody that binds soluble amyloid beta peptide, is being developed for treatment of Alzheimer's disease (AD). Methods: Patients (n = 2042) with mild and moderate AD were randomized 1:1 to 400-mg solanezumab or placebo infusion every 4 weeks for 80 weeks and 1457 patients entered an open-label extension. Magnetic resonance imaging scans monitored for amyloid-related imaging abnormalities-edema/effusion (ARIA-E) and amyloid-related imaging abnormalities-hemorrhage/hemosiderin deposition. Results: Sixteen patients (solanezumab, n = 11; placebo, n = 5) developed ARIA-E during the double-blind phase, and 7 patients developed ARIA-E during the open-label extension as of July 31, 2014. Unique cases are discussed including solanezumab patients who were given solanezumab, while ARIA-E was present and a patient who developed ARIA-E during placebo treatment and again during solanezumab treatment. Discussion: Asymptomatic ARIA-E was detected in solanezumab-treated and placebo-treated AD patients. ARIA-E occurs infrequently during solanezumab and placebo treatments but may occur repeatedly in some patients.

AB - Introduction: Solanezumab, a humanized monoclonal antibody that binds soluble amyloid beta peptide, is being developed for treatment of Alzheimer's disease (AD). Methods: Patients (n = 2042) with mild and moderate AD were randomized 1:1 to 400-mg solanezumab or placebo infusion every 4 weeks for 80 weeks and 1457 patients entered an open-label extension. Magnetic resonance imaging scans monitored for amyloid-related imaging abnormalities-edema/effusion (ARIA-E) and amyloid-related imaging abnormalities-hemorrhage/hemosiderin deposition. Results: Sixteen patients (solanezumab, n = 11; placebo, n = 5) developed ARIA-E during the double-blind phase, and 7 patients developed ARIA-E during the open-label extension as of July 31, 2014. Unique cases are discussed including solanezumab patients who were given solanezumab, while ARIA-E was present and a patient who developed ARIA-E during placebo treatment and again during solanezumab treatment. Discussion: Asymptomatic ARIA-E was detected in solanezumab-treated and placebo-treated AD patients. ARIA-E occurs infrequently during solanezumab and placebo treatments but may occur repeatedly in some patients.

KW - Alzheimer's disease

KW - Amyloid-related imaging abnormalities

KW - Clinical trials

UR - http://www.scopus.com/inward/record.url?scp=84964422587&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964422587&partnerID=8YFLogxK

U2 - 10.1016/j.dadm.2016.02.004

DO - 10.1016/j.dadm.2016.02.004

M3 - Article

AN - SCOPUS:84964422587

VL - 2

SP - 75

EP - 85

JO - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

JF - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

SN - 2352-8729

ER -